You are here: Industry Insights > Lilly

News List

Lilly licenses non-opioid pain therapeutic from Centrexion pharmaceutical-technology
May 30, 2019
Eli Lilly has signed an agreement to license exclusive global rights for non-opioid pain asset CNTX-0290 from biopharmaceutical company Centrexion Therapeutics.
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions drugs
May 30, 2019
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions.
Lilly oncology suffers another blow as Verzenio slapped with safety warning in Japan fiercepharma
May 29, 2019
Breast cancer therapy Verzenio was counted as one of the key growth drivers at Eli Lilly in the first quarter. But in Japan, where the company said it was seeing “nice uptake,” the drug has run into a safety problem.
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market drugs
May 09, 2019
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market.
Lilly to withdraw cancer drug Lartruvo from global market pharmaceutical-technology
April 28, 2019
Eli Lilly has announced an access programme for patients that wish to continue using its cancer drug Lartruvo (olaratumab) as the company prepares to withdraw the medication from markets worldwide.
Lilly and Avidity Biosciences enter into licensing and research collaboration biospectrumasia
April 25, 2019
Collaboration will pursue therapeutic targets focused on immunology and other indications
Lilly announces sale of legacy antibiotics brands and manufacturing facility in China biospectrumasia
April 23, 2019
Eli Lilly and Company has announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines……
Pfizer, Lilly’s painkiller tanezumab shows mixed results in phase 3 osteoarthritis trial pharmaceutical-business-review
April 23, 2019
Pfizer and Eli Lilly’s phase 3 study has showed mixed results of painkiller tanezumab in the treatment of patients with osteoarthritis (OA).
Lilly, Avidity Biosciences Enter Global R&D Alliance b3cnewswire
April 23, 2019
Will leverage Avidity's technology platform for the discovery, development and commercialization of potential new medicines in immunology and other indications...
Eli Lilly inks deal with ImmuNext to jointly develop therapies for autoimmune diseases firstwordpharma
March 28, 2019
Eli Lilly and ImmuNext announced a collaboration to jointly study a preclinical novel target that could facilitate the development of new treatments for autoimmune disorders that regulate immune cell metabolism.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page